ALLO

Allogene TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$2.40

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Base case

35%

Probability

Target price

$1.25

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Most likely

B-

Bear case

45%

Probability

Target price

$0.55

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-14

AI commentary

The October 13 anchor of $1.29 is below the prior baseline's September 21 anchor of $1.69, consistent with continued caution, although those two points do not establish the cause of the decline. Stored Zacks coverage reported an approximately 11.1% share loss in the month after Q2 results and said estimates had moved upward; no dependable current analyst target-change set was supplied. Social, options, short-interest and employee measures were unavailable; zeros above are placeholders, not observed neutral readings. The Q2 company release and its SEC-filed exhibit support the clinical timetable and financial figures [#SEC-8K-2026-08-12].

RankAlpha Sentiment Codex - 2026-10-14

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventALPHA3 site activation and enrollment executionHigh impact

After activating more than 80 ALPHA3 sites, Allogene expects approximately 100 active sites by year-end 2026. Reaching that goal could support enrollment confidence, but site count alone would not establish clinical benefit [#SEC-8K-2026-08-12].

2026-12-31catalystQ4 2026 ALLO-329 clinical updateHigh impact

Allogene expects clinical and translational data from the Phase 1 RESOLUTION autoimmune-disease trial in Q4 2026. Activity, safety and results from cohorts testing reduced or no conventional lymphodepletion are the key questions. The timing is a company expectation, not a confirmed readout date [#SEC-8K-2026-08-12].

2027-06-30catalystMid-2027 ALPHA3 interim event-free-survival analysisHigh impact

The initial 24-patient assessment found MRD negativity in 7 of 12 cema-cel patients versus 2 of 12 under observation. Allogene expects the next program update, tied to an interim event-free-survival analysis, in mid-2027. Whether early MRD clearance translates into durable clinical benefit remains unproven [#SEC-8K-2026-08-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-14 • Updated nightlySource: Internal modelMethodology